UA79942C2 - Levonorgestrel pharmaceutical composition and use thereof for emergency contraception - Google Patents

Levonorgestrel pharmaceutical composition and use thereof for emergency contraception Download PDF

Info

Publication number: UA79942C2
Authority: UA; Ukraine
Prior art keywords: levonorgestrel; hours; active ingredient; emergency contraception; coitus
Prior art date: 2001-11-27

Application number

UA20040504015A

Other languages

English (en)

Ukrainian (uk)

Inventor

Luc Paul Van

Illeshn Balog

Katalin Komandi

Laslo Nemesh

Zholt Sabo

Original Assignee

Richter Gedeon Vedieceti Djar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-27

Filing date

2002-11-26

Publication date

2007-08-10

2002-11-26 Application filed by Richter Gedeon Vedieceti Djar filed Critical Richter Gedeon Vedieceti Djar

2007-08-10 Publication of UA79942C2 publication Critical patent/UA79942C2/uk

Links

WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 title claims abstract description 38
229960004400 levonorgestrel Drugs 0.000 title claims abstract description 38
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
239000000203 mixture Substances 0.000 claims abstract description 20
239000004480 active ingredient Substances 0.000 claims abstract description 11
239000000654 additive Substances 0.000 claims abstract 2
239000003085 diluting agent Substances 0.000 claims abstract 2
239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
239000003381 stabilizer Substances 0.000 claims abstract 2
238000002360 preparation method Methods 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims 2
239000000796 flavoring agent Substances 0.000 claims 1
235000013355 food flavoring agent Nutrition 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 2
239000003826 tablet Substances 0.000 description 17
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
230000000694 effects Effects 0.000 description 13
238000000034 method Methods 0.000 description 10
235000019359 magnesium stearate Nutrition 0.000 description 7
230000002254 contraceptive effect Effects 0.000 description 6
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
206010028813 Nausea Diseases 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
206010047700 Vomiting Diseases 0.000 description 5
229940075614 colloidal silicon dioxide Drugs 0.000 description 5
239000003433 contraceptive agent Substances 0.000 description 5
229960002568 ethinylestradiol Drugs 0.000 description 5
229960001021 lactose monohydrate Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
230000008693 nausea Effects 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
230000002513 anti-ovulatory effect Effects 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
238000005469 granulation Methods 0.000 description 4
230000003179 granulation Effects 0.000 description 4
229940016286 microcrystalline cellulose Drugs 0.000 description 4
235000019813 microcrystalline cellulose Nutrition 0.000 description 4
239000008108 microcrystalline cellulose Substances 0.000 description 4
239000006187 pill Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
230000008673 vomiting Effects 0.000 description 4
230000009471 action Effects 0.000 description 3
229940011871 estrogen Drugs 0.000 description 3
239000000262 estrogen Substances 0.000 description 3
239000008187 granular material Substances 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000019255 Menstrual disease Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
210000004696 endometrium Anatomy 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000005243 fluidization Methods 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
238000002513 implantation Methods 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000016087 ovulation Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
238000005507 spraying Methods 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
238000005303 weighing Methods 0.000 description 2
206010000084 Abdominal pain lower Diseases 0.000 description 1
206010006313 Breast tenderness Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
CSUXYWBSYIKFBC-KTTGPIHOSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 CSUXYWBSYIKFBC-KTTGPIHOSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
229940124558 contraceptive agent Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
231100000546 inhibition of ovulation Toxicity 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000011599 ovarian follicle development Effects 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
230000021962 pH elevation Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000003408 postcoitus contraceptive agent Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

UA20040504015A 2001-11-27 2002-11-26 Levonorgestrel pharmaceutical composition and use thereof for emergency contraception UA79942C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0105173A HU227198B1 (en)	2001-11-27	2001-11-27	Pharmaceutical composition for emergency contraception containing levonorgestrel
PCT/HU2002/000129 WO2003045397A1 (fr)	2001-11-27	2002-11-26	Posologie et composition pharmaceutique pour contraception d'urgence

Publications (1)

Publication Number	Publication Date
UA79942C2 true UA79942C2 (en)	2007-08-10

Family

ID=89998939

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040504015A UA79942C2 (en)	2001-11-27	2002-11-26	Levonorgestrel pharmaceutical composition and use thereof for emergency contraception

Country Status (33)

Country	Link
US (1)	US20050288264A2 (fr)
EP (1)	EP1448207B1 (fr)
JP (1)	JP2005516904A (fr)
KR (1)	KR100908161B1 (fr)
CN (1)	CN1551774A (fr)
AP (1)	AP1849A (fr)
AT (1)	ATE293978T1 (fr)
AU (1)	AU2002347401A1 (fr)
BR (1)	BR0210595A (fr)
CA (1)	CA2450359C (fr)
DE (1)	DE60203929T2 (fr)
DK (1)	DK1448207T3 (fr)
EA (1)	EA006545B1 (fr)
EC (1)	ECSP045171A (fr)
ES (1)	ES2239727T3 (fr)
GE (1)	GEP20063882B (fr)
HR (1)	HRP20040584B1 (fr)
HU (1)	HU227198B1 (fr)
IL (1)	IL159394A0 (fr)
IS (1)	IS2691B (fr)
MA (1)	MA27076A1 (fr)
MX (1)	MXPA04005104A (fr)
NO (1)	NO333984B1 (fr)
NZ (1)	NZ530056A (fr)
OA (1)	OA12730A (fr)
PL (1)	PL206010B1 (fr)
PT (1)	PT1448207E (fr)
RS (1)	RS50768B (fr)
SI (1)	SI1448207T1 (fr)
TN (1)	TNSN04048A1 (fr)
UA (1)	UA79942C2 (fr)
WO (1)	WO2003045397A1 (fr)
ZA (1)	ZA200404114B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2531929T3 (es) *	2006-12-20	2015-03-20	Teva Women's Health, Inc.	Formas de dosificación solidas que se disgregan en la boca que comprenden progestina y métodos para hacer y usar las mismas
EA201070715A1 (ru) *	2007-12-20	2011-02-28	Тева Вимен'С Хелс, Инк.	Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
US8512745B2 (en)	2008-12-08	2013-08-20	Laboratoire Hra Pharma	Ulipristal acetate tablets
US9180131B2 (en)	2008-12-12	2015-11-10	Laboratoire Hra Pharma	Method for contraception
HRP20161437T1 (hr)	2009-04-14	2017-02-10	Laboratoire Hra Pharma	Postupak hitne kontracepcije
KR20120044307A (ko)	2009-06-23	2012-05-07	바이엘 파마 악티엔게젤샤프트	긴급 피임용 제약 조성물
CN101732324B (zh) *	2009-12-31	2011-12-07	广州朗圣药业有限公司	一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法
WO2012164096A1 (fr)	2011-06-01	2012-12-06	Estetra S.A.	Procédé pour la production d'intermédiaires d'estétrol
BR112013030833B1 (pt)	2011-06-01	2019-09-03	Estetra S A	processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
EP2383279A1 (fr)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Procédé de préparation d'estetrol
BR112014003113A2 (pt) *	2011-08-11	2017-03-14	Estetra Sprl	método de contracepção de emergência em uma fêmea mamífero
JP6254605B2 (ja)	2012-11-22	2017-12-27	バイエル・ファルマ・アクティエンゲゼルシャフト	「オンデマンド」避妊のためのレボノルゲストレルおよびｃｏｘ阻害剤を含む医薬組成物の使用および投与計画
CA2913085A1 (fr)	2013-05-23	2014-11-27	Bernhard Lindenthal	Composition pharmaceutique et son utilisation, ainsi que schema d'emploi de cette composition pharmaceutique pour la contraception a la demande
CN103877058A (zh) *	2014-03-26	2014-06-25	邵娜	一种左炔诺孕酮片及其制备工艺
LT3310345T (lt)	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
NZ737945A (en)	2015-06-18	2023-06-30	Estetra Sprl	Orodispersible dosage unit containing an estetrol component
RS57328B1 (sr)	2015-06-18	2018-08-31	Mithra Pharmaceuticals S A	Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (fr)	2015-06-18	2016-12-22	Mithra Pharmaceuticals S.A.	Comprimé orodispersible contenant de l'estétrol
CA3178291A1 (fr)	2016-08-05	2018-04-12	Estetra Srl	Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es)	2018-04-19	2021-01-27	Estetra Sprl	Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
CN110917154A (zh) *	2019-12-12	2020-03-27	上海信谊天平药业有限公司	一种左炔诺孕酮片的制备方法
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物
WO2022026901A2 (fr) *	2020-07-30	2022-02-03	Acer Therapeutics Inc.	Antagonistes nk pour la contraception
CN119523923A (zh) *	2024-11-21	2025-02-28	华中药业股份有限公司	一种左炔诺孕酮片及其制备方法

2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
2002
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko not_active Expired - Lifetime
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 CA CA2450359A patent/CA2450359C/fr not_active Expired - Lifetime
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/fr not_active Ceased
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 EP EP02783334A patent/EP1448207B1/fr not_active Expired - Lifetime
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0105173A3 (en)	2004-03-29
ZA200404114B (en)	2005-10-26
KR100908161B1 (ko)	2009-07-16
IL159394A0 (en)	2004-06-01
BR0210595A (pt)	2004-06-08
US20050288264A2 (en)	2005-12-29
HUP0105173A2 (hu)	2003-08-28
ES2239727T3 (es)	2005-10-01
AP2004003046A0 (en)	2004-06-30
RS50768B (sr)	2010-08-31
EP1448207B1 (fr)	2005-04-27
PT1448207E (pt)	2005-08-31
DE60203929T2 (de)	2006-01-19
OA12730A (fr)	2006-06-28
CA2450359C (fr)	2011-05-10
CN1551774A (zh)	2004-12-01
IS2691B (is)	2010-10-15
WO2003045397A1 (fr)	2003-06-05
NZ530056A (en)	2005-02-25
PL369520A1 (en)	2005-04-18
IS7065A (is)	2003-12-05
ATE293978T1 (de)	2005-05-15
TNSN04048A1 (en)	2006-06-01
US20050032755A1 (en)	2005-02-10
NO20041607L (no)	2004-04-20
SI1448207T1 (en)	2005-10-31
MXPA04005104A (es)	2004-08-19
EA200400731A1 (ru)	2004-12-30
NO333984B1 (no)	2013-11-04
CA2450359A1 (fr)	2003-06-05
ECSP045171A (es)	2004-08-27
MA27076A1 (fr)	2004-12-20
AU2002347401A1 (en)	2003-06-10
KR20040066088A (ko)	2004-07-23
AP1849A (en)	2008-05-23
HRP20040584A2 (en)	2005-02-28
GEP20063882B (en)	2006-07-25
DE60203929D1 (de)	2005-06-02
EP1448207A1 (fr)	2004-08-25
HRP20040584B1 (en)	2012-11-30
HU227198B1 (en)	2010-10-28
PL206010B1 (pl)	2010-06-30
EA006545B1 (ru)	2006-02-24
JP2005516904A (ja)	2005-06-09
DK1448207T3 (da)	2005-06-27
RS4204A (sr)	2007-02-05
HUP0105173D0 (en)	2002-02-28

Publication	Publication Date	Title
ES2239727T3 (es)	2005-10-01	Regimen de dosificacion y composicion farmaceutica para anticoncepcion de emergencia.
RU2542779C2 (ru)	2015-02-27	Способ контрацепции, используемый по мере необходимости
CN102458386B (zh)	2016-04-06	用于紧急避孕的药物组合物
WO2010033188A2 (fr)	2010-03-25	Formes posologiques pour la suppression menstruelle, la contraception, et l'hormonothérapie substitutive, et procédés pour les administrer
JP6254605B2 (ja)	2017-12-27	「オンデマンド」避妊のためのレボノルゲストレルおよびｃｏｘ阻害剤を含む医薬組成物の使用および投与計画
PT81217B (pt)	1987-09-30	Processo para a preparacao de uma nova combinacao contraceptiva com efeito sinergico
WO1999025360A2 (fr)	1999-05-27	Regime progestatif-antiprogestatif
HK1070275A (en)	2005-06-17	Dosage regimen and pharmaceutical composition for emergency contraception
CA3234836A1 (fr)	2023-03-16	Regime contraceptif comprenant un niveau reduit d'oestrogene
KR20010110807A (ko)	2001-12-13	조합 치료에서의 항프로게스타겐의 용도